HC Wainwright Has Bearish Estimate for CATX Q3 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.31) per share for the quarter, down from their prior forecast of ($0.30). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics' FY2025 earnings at ($1.17) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.32) EPS.

A number of other brokerages have also recently commented on CATX. Wedbush reiterated an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Royal Bank of Canada lowered their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research report on Thursday, March 27th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price on the stock. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Finally, Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $12.50.

Perspective Therapeutics Stock Performance

Shares of NYSE:CATX traded down $0.12 during trading on Wednesday, hitting $2.39. 656,911 shares of the company's stock were exchanged, compared to its average volume of 1,037,451. The business's 50-day simple moving average is $2.24 and its 200 day simple moving average is $3.26. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $16.55.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd acquired a new stake in Perspective Therapeutics in the 4th quarter valued at about $33,000. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics during the 4th quarter worth $34,000. National Bank of Canada FI raised its stake in Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after acquiring an additional 10,998 shares in the last quarter. ProShare Advisors LLC lifted its stake in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after buying an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. acquired a new stake in Perspective Therapeutics during the 4th quarter worth $51,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Insiders Place Their Bets

In other news, CEO Johan M. Spoor acquired 22,026 shares of the business's stock in a transaction dated Friday, March 28th. The shares were acquired at an average cost of $2.24 per share, with a total value of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares of the company's stock, valued at approximately $133,017.92. This trade represents a 58.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Juan Graham purchased 33,333 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The shares were acquired at an average cost of $2.25 per share, with a total value of $74,999.25. Following the completion of the transaction, the chief financial officer now directly owns 35,354 shares in the company, valued at $79,546.50. The trade was a 1,649.33% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 115,696 shares of company stock valued at $256,344. 3.72% of the stock is currently owned by corporate insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.